PACIFIC Trial (2017): Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

PACIFIC Trial visual abstract

PACIFIC Trial Summary (NEJM 2018): Scott J et al. randomized 713 patients with stage III unresectable nonsmall cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy were randomized to either Durvalumab 10mg/kg body weight twice weekly for 12 months (n=473) or matching placebo (n=236). The primary objective was to assess if Durvalumab prolongs survival and increases the time to death or prevent distant metastasis in patients with stage 3 unresectable nonsmall cell lung cancer. The primary outcome of 24-month overall survival rate was significantly higher in the Durvalumab group, 66.3% compared to 55.6% in the placebo group. The authors concluded that Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified.

Source: 2018, Durvalumab in non small cell lung cancer, NEJM